



March 25, 2013 06:00 AM Eastern Daylight Time

Revance Therapeutics Announces Appointment of Lauren Silvernail as Chief Financial Officer

NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Revance) today announced the appointment of Lauren Silvernail as Chief Financial Officer and Executive Vice President of Corporate Development effective immediately. Ms. Silvernail succeeds David Styka, who will transition to Senior Vice President Finance & Administration.

As Chief Financial Officer and Executive Vice President of Corporate Development, Mrs. Silvernail will oversee Revance's finance and accounting, corporate development and investor and public relations. Mrs. Silvernail was most recently the Chief Financial Officer and Vice President of Corporate Development at ISTA Pharmaceuticals, Inc., a publicly traded ophthalmic pharmaceutical company based in Irvine, California. Mrs. Silvernail was a key architect of the company's growth and financing plans, which transformed ISTA from a development stage organization to the third largest branded ophthalmic pharmaceutical company in the U.S., with over 330 employees and 2011 sales of \$160 million. In 2012, Mrs. Silvernail and her team closed the sale of ISTA to Bausch + Lomb. Prior to ISTA, Mrs. Silvernail served in various operating and corporate development positions for Allergan, most recently as Vice President of Business Development, where she led and closed acquisitions, licensing and commercial co-promotion transactions.

“With David’s change to SVP of Finance and his continued contribution to Revance’s success, I am confident there will be a smooth transition and seamless leadership of our finance team.”

"We are very pleased to welcome Lauren to Revance. She is extremely well-qualified to lead the company's finance and corporate development activities as we grow our global dermatology and therapeutic botulinum platform. As an experienced Chief Financial Officer and executive in the biopharmaceutical field, Lauren has demonstrated strength in strategy and execution and she will be an instrumental member of the organization," said Dan Browne, President and Chief Executive Officer. "With David's change to SVP of Finance and his continued contribution to Revance's success, I am confident there will be a smooth transition and seamless leadership of our finance team."

About RT001 and RT002

RT001 Botulinum Toxin Type A Topical Gel is an investigational product currently in US phase 3 trials for the topical delivery of botulinum toxin type A to reduce the severity of crow's feet wrinkles by temporarily relaxing the orbicularis oculi muscle around the eyes. RT001 is also currently in phase 2 trials for the topical treatment of hyperhidrosis (excessive sweating), and chronic migraine headache.

RT002 is an investigational, injectable neurotoxin that integrates Revance's proprietary, purified botulinum toxin type A molecule with the patented TransMTS[®] peptide technology. RT002 is currently in Phase 1/2 trials.

About Revance Therapeutics, Inc.

Revance Therapeutics, Inc. (Revance) is a specialty biopharmaceutical company which develops neuromodulation products in dermatology and therapeutic medicine. Revance has developed a platform technology, TransMTS[®] that enables local, targeted delivery of botulinum toxin and other potent macromolecules across skin without patches, needles or other invasive procedures.

For more information, see the company website at www.revance.com

Contacts

Revance Therapeutics, Inc.
Niquette Hunt, 510-742-3464
Senior Vice President of Commercial Development
nhunt@revance.com

